Kiley Perethian, DO
Family Medicine · Kingsport, TNNPI 1851852321
Payments from drug & device makers
Across 168 payments — averaging $14.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$553
- AbbVie$380
- GSK$304
- Lilly USA, LLC$179
- Exact Sciences$154
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$140
- plus $784 from 20 others
What the payments were for
- Food & beverage$2,47799%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $553 |
| AbbVie | 32 | $380 |
| GSK | 21 | $304 |
| Lilly USA, LLC | 10 | $179 |
| Exact Sciences | 7 | $154 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $140 |
| Bayer | 7 | $130 |
| Xeris Pharmaceuticals, Inc. | 6 | $125 |
| Inogen, Inc. | 4 | $64 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| AstraZeneca | 3 | $56 |
| Merck | 2 | $38 |
| Pfizer | 2 | $37 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Amgen | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Gilead | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
How this compares
$2,494 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 223 | $225,807 |
| OzempicSemaglutide | 178 | $207,806 |
| JardianceEmpagliflozin | 135 | $159,578 |
| MounjaroTirzepatide | 36 | $48,989 |
| XareltoRivaroxaban | 46 | $41,918 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $36,695 |
| JanuviaSitagliptin Phosphate | 31 | $35,672 |
| VraylarCariprazine Hcl | 20 | $31,916 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $24,094 |
| TrulicityDulaglutide | 21 | $23,863 |
| KerendiaFinerenone | 21 | $23,468 |
| LinzessLinaclotide | 32 | $21,209 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $15,765 |
| FarxigaDapagliflozin Propanediol | 21 | $15,715 |
| EntrestoSacubitril/Valsartan | 17 | $15,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $37 | $236,924250 claims |
| Novo NordiskOzempic | $553 | $207,806178 claims |
| Lilly USA, LLCMounjaro, Trulicity | $179 | $72,85257 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Symbicort | $56 | $70,567109 claims |
| AbbVieVraylar, Linzess, Synthroid | $380 | $55,686113 claims |
| MerckJanuvia | $38 | $35,67231 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $304 | $34,52247 claims |
| BayerKerendia | $130 | $23,46821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Kingsport
- Emily HubbsKingsport$2.8M
- Curtis JantziKingsport$1.3M
- Warren JonesKingsport$27K
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.